TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00901316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine Measures Group
Description: Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bleach Bath Group (Bleach plus routine measures)
Description: Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths.
Study: NCT00615511

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo pregnenolone
Description: Sugar pill, taken twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pregnenolone
Description: 500mg in tablet form taken orally twice a day
Study: NCT02197130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
Study: NCT01594762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical pexiganan cream 0.8%
Description: 14 days of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo cream
Description: 14 days of treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard wound care
Description: 14 days of treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard wound care
Description: 14 days of treatment
Study: NCT02320669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triostat
Description: Bolus of Triiodothyronine followed by infusion for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bolus of Placebo followed by infusion for 48 hours
Study: NCT02151383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Serelaxin was administered intravenously for up to 48 hours.
Study: NCT00172133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX1-11 (drug)
Description: 100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
Study: NCT03915821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECT
Description: Electroconvulsive therapy was administered by using bidirectional constant current, brief-pulse devices. During the procedure, the patients were sedated using propofol or thiopenthal. Succinylcholine (1 mg/kg) was used as muscle relaxant, and glycopyrrolate (0.2 mg) or atropine was used as an anticholinergic agent when necessary. The mean charges were 351 (SD, 143) mC for the unilateral electrode placement group, 417 (SD, 192) mC for the bitemporal electrode placement group and 260 (SD, 76) mC for the bifrontal electrode placement group, (Brus, Ole MSc, 2017).~The average course of treatment for depression is 6 to 12 treatments, but some patients may require as many as 20 treatments,
Study: NCT03105791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formal education regarding opioid usage
Description: Participannts watched a 2 minute video and were given educational materials
Study: NCT02854553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: ultra sound guides Transversus abdominis plane block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectus sheath block
Description: ultrasound guided rectus sheath block
Study: NCT04162535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~* Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~* Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~* Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood extraction
Description: The patients will donate after consent 10 ml of blood prior and after surgery for further study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood extraction
Description: The patients will donate after consent 10 ml of blood prior and after surgery for further study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood extraction
Description: The patients will donate after consent 10 ml of blood prior and after surgery for further study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients will receive a general anesthesia with Propofol as anesthetic agent
Study: NCT03219567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: Optical coherence tomography (OCT) is a non-contact, micrometer scale imaging technique, it provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D.~The study team will develop the hardware systems and software algorithms necessary to enable simultaneous OCT imaging of all the refractive surfaces of the eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: Optical coherence tomography (OCT) is a non-contact, micrometer scale imaging technique, it provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D.~The study team will develop the hardware systems and software algorithms necessary to enable simultaneous OCT imaging of all the refractive surfaces of the eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in the body.
Study: NCT04390568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimap
Description: Spesolimap

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimap
Description: Spesolimap

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimap
Description: Spesolimap

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimap
Description: Spesolimap

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimap
Description: Spesolimap
Study: NCT02448004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872
Description: Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
Study: NCT00880763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Description: Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Description: Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Description: Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon (peg-IFN)
Description: Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
Study: NCT01649271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: at MTD level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 3-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: at MTD level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: escalating dose
Study: NCT00880763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (peg-IFN)
Description: Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (peg-IFN)
Description: Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon (peg-IFN)
Description: Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
Study: NCT00444925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine tartrate
Description: 4 mg once daily (OD) for 12 weeks
Study: NCT00880763

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to vaniprevir oral capsule twice daily for 28 days
Study: NCT03695861

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-body 18F-FDG PET-CT scan
Description: A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.
Study: NCT04427644

Intervention type: PROCEDURE
Intervention: Laparascopic Sleeve Gastrectomy
Description: Operations performed for complciation of laparascopic sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: Laparascopic Sleeve Gastrectomy
Description: Operations performed for complciation of laparascopic sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: İnterventional radiologic drainage
Description: İnterventional radiologic drainage of gastric leakage

Intervention type: PROCEDURE
Intervention: İnterventional radiologic drainage
Description: İnterventional radiologic drainage of gastric leakage
Study: NCT02186990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 2,5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate
Description: 0,3 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate-propofol
Description: 0,15 mg/kg etomidate + 1,25 mg/kg propofol
Study: NCT04427644

Intervention type: PROCEDURE
Intervention: İnterventional radiologic drainage
Description: İnterventional radiologic drainage of gastric leakage

Intervention type: DIAGNOSTIC_TEST
Intervention: Complte Blood Count and Biochemical evaluation
Description: blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Complte Blood Count and Biochemical evaluation
Description: blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Complte Blood Count and Biochemical evaluation
Description: blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Complte Blood Count and Biochemical evaluation
Description: blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Complte Blood Count and Biochemical evaluation
Description: blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
Study: NCT00307242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil
Study: NCT01792245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Study: NCT04427644

Intervention type: DIAGNOSTIC_TEST
Intervention: Complte Blood Count and Biochemical evaluation
Description: blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Complte Blood Count and Biochemical evaluation
Description: blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography
Description: Admitted to observe leakage
Study: NCT03009812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Longitudinal uterine incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse uterine incision
Study: NCT04427644

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography
Description: Admitted to observe leakage

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography
Description: Admitted to observe leakage
Study: NCT03475901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality App
Description: Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
Study: NCT02560532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Concentrated solution for intravenous injection
Study: NCT00003997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irofulven
Study: NCT03884491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine IV
Description: an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours
Study: NCT05126940

Intervention type: DIAGNOSTIC_TEST
Intervention: we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
Description: Patients were placed in a semi-recumbent or supine position depending on their respiratory tolerance. For each side of the chest, 4 zones have to be assessed : 2 anterior and 2 lateral. The operator should calculate the number of B-lines when present .
Study: NCT00166036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 12 Weeks of Oral Atorvastatin 10 mg therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 12 Weeks of Oral Pravastatin 80 mg therapy.
Study: NCT00752830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328
Description: Oral capsule, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328
Description: Oral capsule, single dose
Study: NCT04064619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate 5 MG
Description: gradual weaning of drug vs. stopping

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate 5 MG
Description: gradual weaning of drug vs. stopping
Study: NCT02771795

Intervention type: DRUG
Intervention: Herceptin (trastuzumab)
Description: Intravenous administration

Intervention type: DRUG
Intervention: SB3 (proposed trastuzumab biosimilar)
Description: Intravenous administration
Study: NCT04650503

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00599898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
Study: NCT00713999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with anti-STI and anti-schistosoma regimens
Description: Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
Study: NCT01302613

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: 5-FU
Description: 5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin
Description: Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m2 IV on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation
Description: 28-30 fractions of radiation, given once a day, five days per week (Monday-Friday, except for holidays). The prescribed fraction dose is 180 cGy; the total radiation dose is thus 5040-5400 cGy. The primary treatment fields will be treated with 25 fractions of 180 cGy/fraction with a boost of 3-5 fractions of 180 cGy subsequently delivered.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: total mesorectal excision
Description: Optimal surgical technique involving use of total mesorectal excision (TME) is mandated. The type of surgery, either low anterior resection with sparing of the sphincter mechanism or sphincter-eliminating abdominoperineal resection (APR), will be at the discretion of the attending surgeon.
Study: NCT05402774

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: point-of-care ultrasound
Description: point-of-care ultrasound
Study: NCT03276221

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Abstinence
Description: Cannabis users randomized to this condition will be enrolled in a contingency management intervention for 30 days of cannabis abstinence.
Study: NCT01705236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.
Study: NCT00217516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selenium
Description: Given orally
Study: NCT01016093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01140490

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Sub-total Parathyroidectomy
Description: Sub-total Parathyroidectomy
Study: NCT02816866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: empowered primary care model
Description: mode of survivorship care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specialty survivor clinic
Description: mode of survivorship care